Know Cancer

or
forgot password

Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab


N/A
18 Years
N/A
Open (Enrolling)
Both
Non-Hodgkin Lymphoma (NHL)

Thank you

Trial Information

Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab


Inclusion Criteria:



1. Patients with non-Hodgkin's lymphoma, treated with rituximab (with a range of 6-12
cycles) and who are in remission.

2. Completion of rituximab therapy in the last twelve months before start of the study.

3. Age ≥ 18 years.

4. Signing of informed consent.

Exclusion Criteria:

1. Completion of rituximab therapy 7-8 months before start of the study.

2. Fever at time of vaccination.

3. Previous/known allergic reaction to any of the components of the vaccines given.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Outcome Measure:

Influenza antibody titre

Outcome Time Frame:

3 weeks after vaccination

Safety Issue:

No

Principal Investigator

Minke AE Rab, Drs.

Investigator Role:

Principal Investigator

Investigator Affiliation:

St. Antonius Hospital

Authority:

The Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Study ID:

NL37320.100.11

NCT ID:

NCT01707628

Start Date:

October 2012

Completion Date:

June 2013

Related Keywords:

  • Non-Hodgkin Lymphoma (NHL)
  • NHL
  • influenza vaccination
  • rituximab
  • Influenza, Human
  • Lymphoma
  • Lymphoma, Non-Hodgkin

Name

Location